Benzinga | Oct 5, 2021 07:50AM EDT

EXCLUSIVE: Annovis Bio's Parkinson's Candidate Improves Speed, Motor Function Vs Placebo

* Annovis Bio Inc (NYSE:ANVS) has announced efficacy data from the Phase 2 trial evaluating ANVS401 in Parkinson's disease (PD).

* Data from 54 patients found that once-daily ANVS401 was superior to placebo in improving motor function.

* ANVS401 was well-tolerated and safe, with no adverse effects related to treatment observed.

* Related: Annovis Bio's Stock Trading Higher As Alzheimer's / Parkinson's Candidate Shows Cognitive Improvement.

* Compared to the placebo group, statistically significant improvements in motor-dexterity, speed, and accuracy were observed in patients across doses of ANVS401, compared to placebo.

* Further, patients taking ANVS401 5mg, 20mg, and 80mg also achieved statistically significant improvements from baseline on the same test.

* Patients treated with ANVS401 10mg and 20mg once daily showed statistically significant improvements in several motor & non-motor functions compared to baseline.

* Annovis is still analyzing certain biomarker data from the 54 PD patients.

* The Company plans to request PD and Alzheimer's disease Meeting with FDA on the next steps in clinical development.

* Annovis Bio will host an investor conference call today at 9 a.m. ET.

* Related: Annovis' Alzheimer's/Parkinson's Candidate Protects Nerve Cells Against Ill Effects of Higher Neurotoxic Proteins.

* Price Action: ANVS stock closed 4.17% lower at $30.35 on Monday.